SCHEMBL4739458

SCHEMBL4739458

CCCCC(Nc1cccc(OC)c1)C(=O)NO

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 2/20 0.52
MMP2 P08253 2/20 0.52
PKM P14618 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MMP13 P45452 1/20 0.47
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
MTNR1B P49286 4/20 0.46
CCKBR P32239 2/20 0.46
ANPEP P15144 1/20 0.46
MTNR1A P48039 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 1/20 0.45
EHMT2 Q96KQ7 1/20 0.44
TSHR P16473 1/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4742706 0.87 MMP9 (0.48) MMP9MMP2MMP13CA1CA2
SCHEMBL4742717 0.84 MMP9 (0.57) MMP9MMP2MMP13CA1CA2
SCHEMBL4738597 0.83 HDAC3 (0.47) MMP2CA1CA2CA9CCKBR
SCHEMBL4742096 0.82 HDAC4 (0.50) MMP2CA1CA2CA9ALDH1A1
SCHEMBL4741450 0.82 MMP2 (0.51) MMP9MMP2CA1CA2CA9
SCHEMBL8171821 0.82 ALDH1A1 (0.43) MMP2CA1CA2CA9ALDH1A1
SCHEMBL4739485 0.82 MMP2 (0.48) MMP9MMP2CA9ANPEPMEN1
SCHEMBL4739513 0.82 HDAC8 (0.48) MMP2CA2CA9ALDH1A1MEN1
SCHEMBL4739412 0.81 HDAC8 (0.54) MMP2HSD17B10MMP13CA1CA2
SCHEMBL4738584 0.81 KDM4E (0.45) MMP2CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242174-B2 Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning PANTHERA BIOPHARMA LLC (US) 2012-08-14 US disclosed
US-8242174-B2 Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning PANTHERA BIOPHARMA LLC (US) 2012-08-14 US disclosed
US-20120157462-A1 Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning PANTHERA BIOPHARMA, LLC 2012-06-21 US disclosed
US-20120157462-A1 Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning PANTHERA BIOPHARMA, LLC 2012-06-21 US disclosed
WO-2008094592-A1 HYDROXAMIC ACID DERIVATIVES OF ANILINE USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING PANTHERA BIOPHARNA, LLC (US) 2008-08-07 WO disclosed
WO-2008094592-A1 HYDROXAMIC ACID DERIVATIVES OF ANILINE USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING PANTHERA BIOPHARNA, LLC (US) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157462-A1 Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning ANTXR2, AGXT, AADAC MMP9 809/4885MMP2 35/4885PKM 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.